Overview

A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers

Status:
Completed

Trial end date:
2014-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability and Pharmacokinetics/Pharmacodynamics of multiple doses of GCC-4401C in healthy male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Green Cross Corporation

Collaborator:

Parexel

Treatments:

Factor Xa Inhibitors
Rivaroxaban